Development of an Excel Program for the Updated Eighth American Joint Committee on Cancer Breast Cancer Staging System.
- Author:
Jaewon JO
1
;
Eui Tae KIM
;
Jun Won MIN
;
Myung Chul CHANG
Author Information
- Publication Type:Original Article
- Keywords: Breast; Neoplasm staging; Software
- MeSH: Biomarkers; Breast Neoplasms*; Breast*; Carcinoma in Situ; Drug Therapy; Humans; Joints*; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Receptor, Epidermal Growth Factor; Receptors, Estrogen; Receptors, Progesterone; Statistics as Topic
- From: Journal of Breast Disease 2018;6(2):35-38
- CountryRepublic of Korea
- Language:Korean
- Abstract: PURPOSE: The eighth American Joint Committee on Cancer staging system for breast cancer was recently published to more accurately predict the prognosis by adding biomarkers such as estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2. However, this system is very complicated and difficult to use by clinicians. The authors developed a program to aid in setting up the staging system and confirmed its usefulness by applying it to theoretical combinations and actual clinical data. METHODS: The program was developed using the Microsoft Excel Macro. It was used for the anatomic, clinical and pathological prognostic staging of 588 theoretical combinations. The stages were also calculated the stages using 840 patients with breast cancer without carcinoma in situ or distant metastasis who did not undergo preoperative chemotherapy. RESULTS: The anatomic, clinical and pathological prognostic stages were identical in 240 out of 588 theoretical combinations. In the actual patients' data, stages IB and IIIB were more frequent in clinical and pathological prognostic stages than in the anatomic stage. The anatomic stage was similar to the clinical prognostic stage in 58.2% and to the pathological prognostic stage in 61.9% of patients. Oncotype DX changed the pathological prognostic stage in 2.1% of patients. CONCLUSION: We developed a program for the new American Joint Committee on Cancer staging system that will be useful for clinical prognostic prediction and large survival data analysis.
